“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.
"I think all disciplines go through a process, a journey of being imagined and then becoming a science and then becoming a discipline of...
How does a biopharma background prepare you for the biotech playground? Find out in our latest episode of the Biorasi Few & Far Between...
“Our studies are open for those that have exhausted standard of care, and we're showing improved responses, and the data is promising. So, I...